Purslane galactoglucan and its composition as well as preparation method and application thereof

A novel purslane galactoglucan with a specific structure is isolated and purified to enhance immune response by promoting cytokine secretion and activating the NF-κB pathway, addressing the challenge of complex polysaccharides in Portulaca oleracea and their immune regulatory potential.

CN117209620BActive Publication Date: 2024-12-03KUNMING INST OF BOTANY CHINESE ACAD OF SCI
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202311234681.3
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-09-22
Publication Date
2024-12-03
Estimated Expiration
2043-09-22

AI Technical Summary

Technical Problem

The complex structure of polysaccharides in Portulaca oleracea and the difficulty in understanding their biological efficacy, particularly in regulating immune activity, have hindered the development of effective immunomodulatory applications.

Method used

The isolation and purification of a novel purslane galactoglucan with a specific chemical structure (β(1→4) galactose main chain and α(1→4) and α(1→6) glucose side chains, promoting cytokine secretion and activating the NF-κB signaling pathway to enhance immune response.

Benefits of technology

The purslane galactoglucan effectively regulates immune activity by promoting cytokine secretion and activating the NF-κB pathway, demonstrating potential in immunomodulatory drugs, foods, and cosmetics.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN117209620B_ABST
    Figure CN117209620B_ABST
Patent Text Reader

Abstract

The present invention provides a purslane galactoglucan, a composition thereof, a preparation method thereof and an application thereof, and belongs to the technical field of medicine, food and cosmetics. The purslane galactoglucan has a structure represented by the general formula of Figure 7, wherein n represents the number of sugar repeating units and n is a natural number. The weight average molecular weight of the purslane galactoglucan is 10 kDa~30 kDa, and the polydispersity coefficient is 1~3. In the monosaccharide composition, the molar ratio of galactose:glucose is about 3.3:1. The purslane galactoglucan and the composition containing the purslane galactoglucan have significant activity in activating macrophages to release immune mediators, and the activity is related to the activation of the NF-κB signaling pathway. Therefore, the present invention also discloses purslane galactoglucan and a composition containing the purslane galactoglucan, as well as its application in the preparation of drugs or foods for enhancing immune activity.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of food, medicine and cosmetics, and in particular to a purslane galactoglucan with a novel structure, a composition thereof, a preparation method thereof and an application thereof. Background Art

[0002] Portulaca oleracea L. is an annual fleshy herbaceous plant of the genus Portulacaceae, and is included in the "National Catalogue of Medicine and Food Homologous". This natural green food is widely distributed throughout the world, commonly known as "longevity vegetable" and "global panacea", and is listed by the World Health Organization as one of the most widely used medicinal plants in the world. Portulaca oleracea has a long history of medicinal and edible use. At present, the research on its effective chemical components mainly focuses on alkaloids, polysaccharides, flavonoids, and organic acids. It has been proven that Portulaca oleracea has significant effects in anti-inflammatory, anti-tumor, antibacterial, hypoglycemic, and treatment of skin diseases. However, the chemical structure of polysaccharides in the genus Portulacaceae is extremely complex, and the same plant often contains many different types of polysaccharides. In addition, the biological efficacy of polysaccharides is extremely difficult and needs to be studied in depth. The inventors have conducted systematic chemical and pharmacological studies on purslane polysaccharides, reported for the first time a purslane galactoglucan with a novel structure, and surprisingly found that the polysaccharide has good immunomodulatory activity. Summary of the invention

[0003] The purpose of the present invention is to provide a novel structure of purslane galactoglucan, a pharmaceutical composition with the purslane galactoglucan as an active ingredient, cosmetics thereof, foods containing the purslane galactoglucan, their preparation methods, and the use of the purslane galactoglucan in the preparation of drugs for regulating immune activity, in products for improving the body's immunity, and in the preparation of foods and cosmetics.

[0004] In order to achieve the above-mentioned object of the present invention, the present invention provides the following technical solutions:

[0005] The present invention first provides a novel galactoglucan from purslane, wherein the galactoglucan from purslane has a chemical structure represented by the following general formula:

[0006]

[0007] Wherein: n represents the number of sugar repeating units, and n is a natural number.

[0008] The weight average molecular weight of the purslane galactoglucan of the present invention is 10 kDa to 30 kDa, and the polydispersity coefficient is 1 to 3. The molar ratio of galactose to glucose in the monosaccharide composition is about 3.3:1.

[0009] The galactoglucan of purslane is obtained by extraction and purification from the dry aerial part of Portulaca oleracea L. of the family Portulacaceae.

[0010] The inventors have found through activity studies that the novel purslane galactoglucan can significantly promote the secretion of cytokines such as IL-6, TNF-α and NO by RAW264.7 cells, thereby having the ability to regulate the body's immunity.

[0011] The inventors have found through in-depth pharmacological studies that the purslane galactoglucan can activate the NF-κB signaling pathway by promoting the phosphorylation of P65 and IκB-α in RAW264.7 cells, thereby showing potential immune enhancement properties.

[0012] In order to obtain the purslane galactoglucan with novel structure and outstanding activity, the present invention also provides a method for separating and extracting the purslane galactoglucan from the dry aerial part of purslane Portulaca oleracea L.

[0013] A method for preparing the purslane galactoglucan of the present invention comprises the following steps:

[0014] Step 1: extract the dried aerial part of Purslane with 95% ethanol, discard the extract, and retain the residue.

[0015] Step 2: extracting the above-mentioned medicinal residue with warm water or hot water to obtain a crude purslane polysaccharide solution;

[0016] Step 3: graded alcohol precipitation to obtain crude purslane polysaccharide;

[0017] Step 4: purifying the component with a weight average molecular weight of 10 kDa to 30 kDa in the crude purslane polysaccharide to obtain the purslane galactoglucan.

[0018] Furthermore, the preparation method of the purslane galactoglucan of the present invention specifically comprises the following steps:

[0019] The above steps 1 to 3 include the following steps: crushing the dried aerial part of purslane, defatting it with 95% ethanol, extracting it with warm water or hot water, centrifuging it to remove the residue, and then using ethanol to grade the purslane polysaccharide in the supernatant to make the alcohol concentration reach 40% and 60% respectively, and collecting the precipitate by centrifugation.

[0020] In the present invention, the step of extracting galactoglucan from purslane further comprises the following steps:

[0021] The powder of the dried aerial part of the purslane is defatted twice with 95% ethanol at a solid-liquid ratio of 1:4 to 1:6. The preferred solid-liquid ratio is 1:5. After filtering, the extract is discarded, and the residue is extracted twice with hot water or warm water at a solid-liquid ratio of 1:4 to 1:6. The preferred solid-liquid ratio is 1:5.

[0022] Further, the obtained solution is extracted with hot water or warm water, and after centrifugation, ethanol with a final concentration of 35% to 45%, 55% to 65% and 75% to 85% is added to the supernatant for graded precipitation, and the 55% to 65% alcohol precipitation is collected by centrifugation to obtain purslane galactoglucan. Preferably, the ethanol concentrations of the graded alcohol precipitations are 40% and 60%, respectively.

[0023] In the present invention, the method for refining the galactoglucan from the dried aerial part of Portulaca oleracea in the above step is selected from one or more of quaternary ammonium salt precipitation method, graded alcohol precipitation method, anion exchange chromatography method, and gel exclusion chromatography method. Preferably, one or more of quaternary ammonium salt precipitation method, graded alcohol precipitation method, and anion exchange chromatography method.

[0024] According to the preparation method provided by the present invention, the weight average molecular weight of the obtained purslane galactoglucan is 10kDa-30kDa, the main structure of which is β(1→4) galactan and α(1→4) glucan, and the molar ratio of galactose to glucose monosaccharides is 3.3:1.

[0025] The purslane galactoglucan with a novel structure of the present invention significantly promotes RAW264.7 cells to secrete NO, cytokines IL-6 and TNF-α, etc., thereby having the ability to regulate the body's immunity. The purslane galactoglucan can activate the NF-κB signaling pathway by promoting the phosphorylation of P65 and IκB-α in RAW264.7 cells, thereby showing potential immune enhancement properties.

[0026] The present invention further provides a pharmaceutical composition, which comprises an effective amount of the purslane galactoglucan and a pharmaceutically acceptable carrier.

[0027] A cosmetic comprising an effective amount of purslane galactoglucan and common cosmetic auxiliary materials.

[0028] A food containing the purslane galactoglucan.

[0029] The use of the purslane galactoglucan or its pharmaceutical composition in preparing drugs for regulating immune activity.

[0030] The application of the purslane galactoglucan in the preparation of cosmetics or food.

[0031] Furthermore, the purslane galactoglucan and its pharmaceutical composition can be in the form of oral or parenteral administration. Specifically, the dosage form can be tablets, capsules, lyophilized powder, oral solution or pellets containing purslane galactoglucan as an active ingredient.

[0032] Furthermore, the purslane galactoglucan and the cosmetics thereof can also be used topically, and can be made into dosage forms including but not limited to: facial masks, creams, ointments, gels, and the like.

[0033] An application of the purslane galactoglucan or the pharmaceutical composition in a product for improving body immunity.

[0034] Application of purslane galactoglucan or a composition thereof in the preparation of medicines, foods or cosmetics for regulating immune activity.

[0035] In the present invention, the dosage forms of the purslane galactoglucan and the composition thereof include but are not limited to lyophilized powder, oral solution, capsule, tablet and the like.

[0036] In summary, due to the adoption of the above technical solution, the beneficial effects of the present invention are:

[0037] The purslane galactoglucan prepared by the present invention is reported for the first time. The inventor's cell experimental research has confirmed that the galactoglucan has the effects of promoting the secretion of macrophage factors and improving immunity, and has important potential for drug application.

[0038] The dried aerial part of purslane is extracted and purified by the innovative method provided by the present invention, and a purslane galactoglucan with a novel structure is obtained. Further pharmacological activity studies have shown that the newly discovered purslane galactoglucan has the purpose of regulating immunity. Therefore, the purslane galactoglucan with a novel structure, the preparation method and composition thereof, and the application of the purslane galactoglucan in immunomodulatory drugs and / or foods and / or cosmetics provided by the present invention are all publicly reported for the first time. BRIEF DESCRIPTION OF THE DRAWINGS

[0039] Figure 1 This is a molecular weight distribution curve of galactoglucan POL-2 from Portulaca oleracea;

[0040] Figure 2 This is the HPLC chart of monosaccharide composition of galactoglucan POL-2 from Portulaca oleracea;

[0041] Figure 3 This is the total ion current diagram of methylation of galactoglucan POL-2 from Portulaca oleracea;

[0042] Figure 4 This is the NMR spectrum of galactoglucan POL-2 from Portulaca oleracea. (A) One-dimensional NMR 1 H spectrum; (B) one-dimensional NMR 13 C spectrum; (C)1 H- 1 H COSY spectrum; (D) 1 H- 1 H TOCSY spectrum; (E) 1 H- 13 C HSQC spectrum; (F) 1 H- 13 C HMBC spectrum; (G) 1 H- 1 H ROESY spectrum; (H) HSQC-TOCSY spectrum;

[0043] Figure 5 Effects of galactoglucan from Portulaca oleracea (POL-2) on NO, TNF-α and IL-6 secretion of RAW264.7 cells: (A) Effect on RAW264.7 cell viability; (B) Effect on NO secretion of RAW264.7 cells; (C) Effect on TNF-α secretion of RAW264.7 cells; (D) Effect on IL-6 secretion of RAW264.7 cells; "*" in the figure represents significant difference compared with the blank group, * represents p<0.05, ** represents p<0.01, *** represents p<0.001, n=3;

[0044] Figure 6 Effects of galactoglucan from Portulaca oleracea (POL-2) on the expression of related proteins in the NF-κB pathway of RAW264.7 cells; (A) protein band diagram of P65, IκB-α, p-P65 and p-IκB-α; (B) protein quantification diagram of p-P65 / P65; (C) protein quantification diagram of p-IκB-α / IκB-α; "*" in the figure represents significant difference compared with the blank group, * represents p<0.05, ** represents p<0.01, *** represents p<0.001, n=3;

[0045] Figure 7 The schematic diagram of the structure of the purslane galactoglucan POL-2 of the present invention, wherein: n represents the number of sugar repeating units, and n is a natural number. DETAILED DESCRIPTION

[0046] In order to facilitate the understanding of the present invention, the present invention will be described more comprehensively below, and preferred embodiments of the present invention are provided. However, the present invention can be implemented in many different forms and is not limited to the embodiments described in the present invention. On the contrary, the purpose of providing these embodiments is to make the understanding of the disclosure of the present invention more thorough and comprehensive.

[0047] Unless otherwise defined, all technical and scientific terms used in the present invention have the same meaning as those commonly understood by those skilled in the art of the present invention. The terms used in the specification of the present invention herein are only for the purpose of describing specific embodiments and are not intended to limit the present invention. The term "and / or" used in the present invention includes any and all combinations of one or more related listed items.

[0048] The galactoglucan from purslane according to one embodiment of the present invention has a structure represented by the following general formula:

[0049]

[0050] Wherein: n represents the number of sugar repeating units, and n is a natural number.

[0051] The purslane galactoglucan has a β(1→4) galactose glycoside bond as the main chain, and the side chains are replaced by α(1→4) glucose and α(1→6) glucose.

[0052] The method for preparing the galactoglucan from Purslane according to an embodiment of the present invention comprises the following steps S1 to S4:

[0053] S1: extract the dried aerial part of Portulaca oleracea with 95% ethanol, discard the extract, and retain the residue.

[0054] S2: extracting the above-mentioned medicinal residues with warm water or hot water to obtain a crude purslane polysaccharide solution;

[0055] S3: graded alcohol precipitation to obtain crude purslane polysaccharide;

[0056] S4: purifying the component with a weight average molecular weight of 10 kDa to 30 kDa in the crude purslane polysaccharide to obtain the purslane galactoglucan.

[0057] In a specific example, S1 includes the following steps: crushing the dried aerial part of Purslane, extracting it with 95% ethanol, filtering and retaining the residue.

[0058] The steps of S2 mainly include extracting twice with warm water or hot water, and combining the supernatants after centrifugation to remove residues.

[0059] Then, 95% ethanol was added to the supernatant to a final concentration of 35% to 45%, and the mixture was centrifuged (4000 rpm×10 min) to obtain a 35% to 45% alcohol precipitate and a 35% to 45% alcohol precipitate supernatant. To the 35% to 45% alcohol precipitate supernatant, 95% ethanol was added with stirring to a final alcohol concentration of 55% to 65%, and the mixture was centrifuged to obtain a 55% to 65% alcohol precipitate and an alcohol precipitate supernatant. The 55% to 65% alcohol precipitate was washed with 95% ethanol for 3 times, re-dissolved in water, and then freeze-dried. The crude purslane polysaccharides obtained by the two centrifugations were named POL40 and POL60, respectively.

[0060] The method for refining galactoglucan from purslane is selected from one or more of anion exchange column chromatography, gel exclusion chromatography column method, dialysis method and ultrafiltration method. Specifically, the crude galactoglucan component from purslane can be re-dissolved in deionized water, and then centrifuged to remove a small amount of insoluble matter, and then purified by optional methods such as graded alcohol precipitation, gel exclusion chromatography, dialysis method or ultrafiltration method, and the flow fraction or retentate or permeate containing galactoglucan is collected, and directly vacuum freeze-dried or concentrated under reduced pressure and then alcohol precipitated and dried under reduced pressure to obtain the refined galactoglucan from purslane.

[0061] It is easy for a person skilled in the art to understand that for anion exchange column chromatography, the column material is reasonably selected according to the amount of charge in the purslane polysaccharide component, such as DEAE-Sepharose Fast Flow series, DEAE-52 series, DEAE-32 series and other fillers, and then the column is loaded, the sample is loaded, and the elution solution containing or not containing salt is used to elute and collect the flow fractions in sequence according to the actual performance of each filler. Specifically, the flow fraction eluted with deionized water is generally uncharged, that is, neutral sugar, and the polysaccharide flow fractions with different charge amounts can be graded by subsequent elution with a gradient salt solution. The effluent can be concentrated or not concentrated, and is loaded into a dialysis bag for dialysis or an ultrafiltration membrane bag for ultrafiltration desalination, and the retentate after desalination is collected, and vacuum freeze-dried or vacuum-reduced dried to obtain purified purslane galactoglucan.

[0062] The present invention also provides a method for analyzing the structure of the purslane galactoglucan, comprising the following steps:

[0063] (1) Molecular weight determination: Take a sample of galactoglucan from purslane and use high performance gel exclusion chromatography-differential detection detection method.

[0064] (2) Analysis of monosaccharide composition: A sample of galactoglucan from purslane was hydrolyzed into monosaccharides by acid, and then derivatized with 1-phenyl-3-methyl-5-pyrazolone (PMP). The monosaccharide composition of galactoglucan from purslane was analyzed by high performance liquid chromatography using a chromatographic column filled with octadecylsilane bonded silica gel.

[0065] (3) Methylation analysis: Take a sample of galactoglucan from purslane, use a methyl halide reagent such as iodomethane under alkaline conditions to methylate the polysaccharide, hydrolyze it under alkaline conditions, and then reduce it with sodium borohydride. Use an acid anhydride to acetylate the methylated sugar alcohol, extract it, and then perform gas chromatography-mass spectrometry (GC-MS) analysis to determine the glycosidic bond connection mode of galactoglucan from purslane.

[0066] (4) Nuclear magnetic resonance analysis: A sample of galactoglucan from purslane was dissolved in heavy water, freeze-dried in a vacuum oven, and repeated three heavy water exchanges before dissolving in heavy water. The nuclear magnetic resonance spectrum of the sample was tested, including one-dimensional 1 H.13 C spectrum and two-dimensional 1 H- 1 HCOSY, 1 H- 1 H TOCSY, 1 H- 1 H ROESY, 1 H- 13 C HSQC, 1 H- 13 C HMBC, HSQC-TOCSY correlation spectra.

[0067] (5) Comprehensive data analysis: The analytical data of the above steps are comprehensively analyzed to analyze the chemical structure of galactoglucan from purslane. According to the above structural analysis method, the galactoglucan from purslane extracted and purified by the preparation method of the present invention is structurally analyzed. The results showed that the galactoglucan from purslane showed only one chromatographic peak with good symmetry on the HPGPC gel chromatography. The weight average molecular weight of the polysaccharide POL-2 purified by 60% ethanol graded alcohol precipitation from purslane was about 21000Da, and its polydispersity index was 1.9. The monosaccharide composition showed that the galactoglucan from purslane was composed of galactose and glucose in a ratio of 3.3:1. The methylation analysis showed that the galactoglucan from purslane had 6 different glycosidic bonds: Glcp-(1→, Galp-(1→, →4)-Glcp-(1→, →4)-Galp-(1→, →6)-Glcp-(1→, →4,6)-Galp-(1→; According to the NMR spectrum data, the galactoglucan from purslane can be classified as 1 H and 13 C's signal.

[0068] Based on the above data, the purslane galactoglucan has Figure 7 The structural features shown are: the molar ratio of galactose to glucose is 3.3:1; the β(1→4) galactose glycosidic bond is the main chain, and the side chains are replaced by α(1→4) glucose glycosidic bonds and α(1→6) glucose glycosidic bonds.

[0069] The present invention surprisingly found through pharmacological research that the purslane galactoglucan can activate macrophages, produce NO and release immune-related active substances such as IL-6, TNF-α and other cellular immune factors, and has significant immunomodulatory activity. In addition, it is also found that the immunomodulatory activity of the polysaccharide is related to the activation of the NF-κB signaling pathway.

[0070] To this end, the present invention also provides the use of the purslane galactoglucan in the preparation of immunomodulatory drugs and / or foods.

[0071] The pharmaceutical composition of the embodiment of the present invention comprises the purslane galactoglucan or a pharmaceutically acceptable salt or a pharmaceutically acceptable solvate thereof, and pharmaceutically and / or food and / or cosmetically acceptable excipients. Optionally, the excipients include pharmaceutical excipients, carriers and / or diluents and / or film-forming agents, etc.

[0072] In a specific example, the dosage form of the above-mentioned pharmaceutical composition is an injection, a solid preparation or an oral solution, such as an aqueous injection, a lyophilized powder injection, a capsule, a micropill, an oral solution, etc., and the auxiliary materials include excipients and / or flavoring agents, etc.

[0073] The cosmetic composition of the embodiment of the present invention comprises the purslane galactoglucan and its cosmetically acceptable salt or cosmetically acceptable solvate, and cosmetically acceptable excipients. Optionally, the excipients include cosmetic excipients, carriers and / or diluents / or film-forming agents, etc.

[0074] In a specific example, the dosage form of the above-mentioned cosmetics is a cream or a gel, and the auxiliary materials include excipients and / or diluents, etc.

[0075] The present invention is described in detail below with reference to specific embodiments in conjunction with the accompanying drawings. However, these embodiments do not constitute any limitation to the scope of the claims of the present invention.

[0076] Example 1

[0077] Extraction and purification of galactoglucan from Purslane.

[0078] 1. Extraction of crude polysaccharides from Purslane

[0079] Weigh 500g of the crushed dry aerial part of Purslane, add 2.5L 95% ethanol and extract twice at 65℃, each time for 3h. After filtering, the residue was extracted twice with deionized water at 80℃, each time for 2h. The obtained extract was centrifuged (4000rpm×20min) to take the supernatant; 95% ethanol was added to the supernatant until the alcohol concentration was 40%, and centrifuged (4000rpm×20min) to obtain 40% alcohol precipitate and 40% alcohol precipitation supernatant; 95% ethanol was added to the above 40% alcohol precipitation supernatant under stirring until the alcohol concentration was 60%, and centrifuged (4000rpm×20min) to obtain 60% alcohol precipitate and alcohol precipitation supernatant; 95% ethanol and anhydrous ethanol were washed with 40% and 60% alcohol precipitates respectively, and the precipitates were re-dissolved in water and freeze-dried after centrifugation to obtain 29.3g and 7.5g of crude polysaccharides POL40 and POL60, respectively.

[0080] 2. Refining of Purslane Galacto-glucan

[0081] Take crude polysaccharide POL60, dissolve it in 100mL deionized water, add an equal volume of 10% benzethonium chloride, stir while adding, let stand and centrifuge (4000rpm, 20℃, 15min), add 95% ethanol to the obtained supernatant to make the final alcohol content 80%, stir while adding, let stand and precipitate. The precipitate obtained after centrifugation (4000rpm, 20℃, 15min) is Purslane crude polysaccharide POL60q. Take freeze-dried crude polysaccharide POL60q, re-dissolve it in deionized water, add 95% ethanol to make the final concentration of ethanol 40%, and the precipitate obtained after centrifugation (4000rpm, 20℃, 15min) is POL60q40. After freeze-drying, 100 mg of POL60q40 was taken, dissolved with 4 mL of deionized water, and centrifuged (4000 rpm, 20 ° C, 15 min). The upper liquid was filtered through a 0.45 μm filter membrane and then slowly and evenly injected into the top of the DEAE-Sepharose Fast Flow column. Elute with deionized water, control the flow rate to 0.1 mL / min, collect 2 mL in each tube, and detect its polysaccharide content by phenol-sulfuric acid method. The elution curve of the polysaccharide component was drawn with the absorbance value as the ordinate and the number of tubes as the abscissa. The eluates belonging to the same elution peak were combined, and the sample with the largest area of ​​the elution curve was collected. After reduced pressure concentration, freeze vacuum drying, and multiple enrichments, 100 mg of refined purslane galactoglucan was obtained.

[0082] Example 2

[0083] Structural analysis of galactoglucan from Purslane.

[0084] 1. Experimental Methods

[0085] 1.1. Molecular weight and its distribution

[0086] The molecular weight and distribution of the purslane galactoglucan prepared in Example 1 were analyzed by high performance gel exclusion chromatography-differential detection detection (HPGPC-RID).

[0087] Chromatographic instrument: Agilent technologies 1260 series high performance liquid chromatograph;

[0088] Chromatographic conditions: Shodex OHpak SB-804HQ (8 mm × 300 mm) column; column temperature, 35 °C; differential detector; mobile phase, 0.1 M NaCl, flow rate, 0.5 mL / min;

[0089] Determination process: Take 5 mg of galactoglucan sample from Portulaca oleracea or dextran reference substance with known molecular weight and add mobile phase to prepare a 5 mg / mL solution, pass through a 0.2 μm microporous filter membrane, and analyze 30 μL of the filtrate in a high performance liquid chromatograph, and record the chromatogram. The data is processed using GPC software, a standard curve is drawn, and the data is entered into the equation to calculate the molecular weight.

[0090] 1.2 Monosaccharide composition analysis

[0091] Take 1 mL of monosaccharide standard solution and sample solution, place them in a hydrolysis tube, add 1 mL of 4M trifluoroacetic acid (TFA) solution, mix well, and hydrolyze in a 110°C oven for 4 hours. After the hydrolysis reaction is completed, the hydrolyzate is dried by rotary evaporation until TFA is completely removed, then 200 μL of deionized water is added to dissolve, 200 μL of 0.6M NaOH solution and 400 μL of 0.5M PMP-methanol solution are added in sequence, mixed evenly, and derivatized in a 70°C oven for 1 hour, cooled to room temperature, and 200 μL of 0.6M hydrochloric acid is added to neutralize. Chloroform is then added for full extraction 3 times (2 mL each time), and the aqueous phase is centrifuged (15000 rpm×10 min) and filtered through a 0.2 μm microporous filter membrane for liquid chromatography analysis.

[0092] Chromatographic conditions:

[0093] Instrument: Agilent technologies 1260 series high performance liquid chromatograph;

[0094] Chromatographic column: Hadesil C18-Bio (250 mm × 4.6 mm, 5 μm); column temperature: 25 °C;

[0095] Mobile phase: 0.1 M phosphate buffer-acetonitrile (82:18);

[0096] Elution: flow rate 1 mL / min; injection volume 5 μL; time 50 min;

[0097] Detection: DAD detector, wavelength 250nm.

[0098] 1.3 Methylation analysis

[0099] 1) Methylation reaction: Take 3-5 mg of polysaccharide sample and place it in a 10 mL COD tube. Add 2 mL of methanol to the COD tube and dry it in a vacuum oven. Repeat twice to completely dehydrate the sample. Add 0.5 mL of DMSO to the dehydrated sample and ultrasonically treat it for 20-30 minutes. Add 500 μL of 120 mg / mL NaOH / DMSO suspension to the sample (Note: NaOH / DMSO suspension is prepared in advance: weigh NaOH solid, add appropriate amount of DMSO to reach the desired concentration, use a magnetic stirrer to stir and seal at 25°C overnight), drop the uniform solid NaOH suspension directly onto the sample, and ultrasonically treat it for 30 minutes. The temperature during the ultrasonic treatment process is kept below 40°C.

[0100] Add 800 μL CH3I to the suspension completely dissolved in NaOH / DMSO in batches. Add 200 μL each time for the first two times and then ultrasonically treat for 10 min. Finally, add 400 μL CH3I and ultrasonically treat for 30 min (the temperature during the ultrasonic process cannot exceed 40°C). Protect the reaction from light. After the reaction is completed, add 1 mL of water to terminate, add 3 mL of CH2Cl2 to extract the sample, remove and discard the aqueous phase. Use an equal volume of water to back-extract the CH2Cl2 phase 3 times and spin dry.

[0101] 2) Acid hydrolysis of methylated polysaccharides:

[0102] Add 2 mL of 2 M TFA to the spin-dried sample and hydrolyze at 120°C for 2 h. After the sample is spin-dried, add 2 mL of methanol and spin-dry again. Repeat twice.

[0103] 3) Reduction of methylated monosaccharides:

[0104] The hydrolyzed sample was dissolved in 1 mL of 2M NH4OH (freshly prepared) and added to 1 mL of freshly prepared 1M NaBD4 (with 2M NH4OH as solvent). The sample was sonicated until dissolved and incubated at room temperature (25°C) for 2.5 h. After the reaction was completed, 400 μL of CH3COOH was carefully added. The sample was spin-dried and continued to be spin-dried twice with 1 mL of 5% (v / v) CH3COOH-CH3OH solution, and spin-dried twice with 1 mL of methanol to remove boric acid. Finally, the spin-dried sample was placed in a vacuum drying oven and dried until the sample in the tube did not flow.

[0105] 4) Acetylation of methylated sugar alcohols:

[0106] Add 1 mL of acetic anhydride and 1 mL of pyridine to the above sample, vortex to dissolve, and place at 100°C for 1.5 hours. After the reaction is completed, add 1 mL of water to terminate the reaction. Extract the reaction mixture three times with CHCl3, and then back-extract the CHCl3 layer with water three times. Spin dry the CHCl3 layer, and finally add an appropriate amount of CH3OH and spin dry twice. Add 1 mL of chromatographic grade CHCl3 to the spin-dried sample to dissolve, filter it through a 0.2 μm organic filter membrane, and perform GC-MS analysis.

[0107] GC conditions: DB-5MS quartz capillary column (30m×0.25mm×0.25μm); column temperature: initial temperature 80℃, hold for 1min, program temperature rise 5℃ / min to 250℃, hold for 40min; column flow rate 1.5mL / min; injection port temperature 250℃; split ratio 10:1; carrier gas is high-purity helium, injection volume 1μL.

[0108] MS conditions: ionization mode EI; electron energy 70 eV; transfer line temperature 290 °C; ion source temperature 230 °C; quadrupole temperature 150 °C; mass range 50-600; compared with the CCRC spectral database to determine the glycosidic bond type.

[0109] 1.4 Nuclear magnetic resonance analysis

[0110] Take 15 mg of galactoglucan sample from purslane and dissolve it in 0.5 mL D2O, freeze-dry it, exchange D2O three times, and then dissolve the freeze-dried sample in 0.5 mL D2O (99.9 atom% D, containing 0.05 wt.% 3-(trimethylsilyl)propionic-2,2,3,3-d4 acid, sodium salt as internal standard). Use Bruker 800 MHz NMR spectrometer to measure 1 H / 13 CNMR spectra and 2D spectra 1 H- 1 H COSY, 1 H- 1 H TOCSY, 1 H- 1 H ROESY, 1 H- 13 C HMBC, 1 H- 13 CHSQC and HSQC-TOCSY were analyzed and processed using MestReNova software.

[0111] 2. Experimental results

[0112] The purslane galactoglucan of the invention has the following properties: white or off-white solid, tasteless, easily soluble in water and hygroscopic.

[0113] The results of high performance gel exclusion chromatography showed that ( Figure 1 ), the purslane galactoglucan extracted and purified from purslane has only one symmetrical chromatographic peak, with a weight-average molecular weight (Mw) of 21000Da and a polydispersity coefficient of 1.9.

[0114] The results of monosaccharide composition analysis showed that ( Figure 2 ), the HPLC chart of the purslane galactoglucan after PMP pre-column derivatization showed two peaks of galactose and glucose, with a ratio of about 3.3:1, indicating that the monosaccharide composition of the purslane galactoglucan only contained galactose and glucose.

[0115] The results of methylation analysis showed that ( Figure 3), the purslane galactoglucan has 6 glycosidic bonds: Glcp-(1→, Galp-(1→, →4)-Glcp-(1→, →4)-Galp-(1→, →6)-Glcp-(1→, →4,6)-Galp-(1→.

[0116] Some results of NMR analysis are shown in Figure 4 , detailed 1 H and 13 The assignments of C NMR signals are shown in Tables 1 and 2. 1 In the H NMR spectrum, the low field region δ H The signal at 5.42 ppm is assigned to the terminal hydrogen signal of Glc, from which it is inferred that Glc is in α configuration. H The signal at 4.65 ppm is assigned to the terminal hydrogen signal of Gal, and the proton coupling constant (J H1-H2 ) is 7.8 Hz, which confirms that Gal is in β configuration. Other protons with weaker signals in the low field region may be the terminal hydrogen signals of the residues with a small proportion in the polysaccharide POL-2. H The peaks at 3.40-4.30 ppm are the proton signals of the remaining positions on the sugar ring. Based on the methylation results of the polysaccharide POL60ql, the main structural fragments were named as residues A, B, C, D and E, respectively.

[0117] exist 13 In the C NMR spectrum, the low field region δ C 104.3ppm and δ C The 99.6ppm signals are the terminal carbon signals of residues A and D, which confirm the configuration of Gal and Glc. Figure 4 In (E), the signals of A and the corresponding anomeric hydrogens at 4.65 / 104.3 ppm and 5.42 / 99.6 ppm were assigned.

[0118] Detailed attribution information is provided by 2D NMR spectra. 1 H- 1 In the H COSY spectrum, starting from the terminal hydrogen of residue A, three groups of related hydrogen signals were found, namely (4.65, 3.69 ppm), (3.69, 3.79 ppm) and (3.79, 4.18 ppm), corresponding to H-2 to H-4 of residue A. Similarly, H-2 and H-3 of residue D were also detected by 1 H- 1H COSY related signals were assigned. Combined with HSQC signals, the C-1 to C-4 signals of residue A were assigned, among which C-4 was shifted to 77.6 ppm downfield due to the glycosylation effect. Similarly, C1 to C3 of residue D were assigned. Since residue A and residue D account for a large proportion in the polysaccharide POL60ql and have strong signals, the remaining carbon-hydrogen signals on the sugar ring can be improved according to the HMBC spectrum. In the HMBC spectrum ( Figure 4 F), the correlation signals at (4.65, 77.6ppm) and (4.18, 104.3ppm) indicate that the A residues are connected by β (1→4) glycosidic bonds, which is consistent with the methylation results. In addition, the correlation signals at (5.42, 76.8ppm) and (3.68, 99.6ppm) are attributed to the correlation within the D residues, indicating that the D residues are connected by α (1→4) glycosidic bonds. Judging from the methylation results, residues B, C, and E account for a small proportion in the polysaccharide POL-2. Based on the above data, the chemical structure of this novel purslane galactoglucan is shown as follows:

[0119]

[0120] In the formula, n represents the number of sugar repeating units, and n is a natural number.

[0121] Its structural characteristics are as follows: (1) the galactoglucan from purslane is a novel galactoglucan extracted from the dry aerial part of purslane, wherein the molar ratio of galactose to glucose is 3.3:1; (2) the monosaccharide connection mode of the galactoglucan from purslane is: the β(1→4) galactose glycosidic bond is the main chain, and the side chain is replaced by α(1→4) glucose and α(1→6) glucose. According to the search of domestic and foreign public literature, this arrangement mode and chemical structure of the galactoglucan from purslane has not been publicly reported, and it is the first discovery of the inventor.

[0122] Table 1. Portulaca oleracea galactoglucan 1 Assignment of H NMR

[0123]

[0124] Table 2. Portulaca oleracea galactoglucan 13 C NMR assignment

[0125]

[0126] Example 3

[0127] Experiment on the immunoenhancing activity of galactoglucan from Portulaca oleracea.

[0128] 1. Test articles, reagents and cells

[0129] Purslane galactoglucan, referred to as POL-2, was prepared according to Example 1. Modified Eagle medium, penicillin-streptomycin mixture, Solarbio; Australian fetal bovine serum (FBS), Gibco; lipopolysaccharide (LPS), dimethyl sulfoxide (DMSO), Sigma; NO kit, nitric oxide kit, Shanghai Biyuntian Biotechnology Co., Ltd.; IL-6, TNF-α kit, Suzhou Sizhengbai Biotechnology Co., Ltd.; TNF-α kit, Shanghai Biyuntian Biotechnology Co., Ltd.; NF-κB p65, IκBα, phospho-NF-κB p65 and phospho-IκBα antibodies, Wuhan Sanying Biotechnology Co., Ltd. RAW264.7 cells were purchased from the cell bank of the Committee for the Collection of Typical Cultures of the Chinese Academy of Sciences.

[0130] 2. Experimental Methods

[0131] 2.1 Removal of LPS from samples

[0132] (1) Activate the Detoxi-GelTM Endotoxin Removing gel column with 5 resin bed volumes of 1% sodium deoxycholate, and then regenerate the detoxifying gel resin by washing with 10 resin bed volumes of sterile water for injection to remove the detergent. Regenerate the resin before each use.

[0133] (2) Equilibrate the detoxified gel resin with 5 resin bed volumes of sterile water for injection.

[0134] (3) Weigh 20 mg of galactoglucan POL-2 sample and dissolve it in 1 mL of sterile water for injection. Add the sample to the column and start collecting the sample. After the sample enters the column material, add an aliquot of pyrogen-free buffer or water, stop the column flow, incubate for 1 h, collect the mobile phase, add 1 mL of sterile water for injection, and collect the mobile phase. A total of 5 mL of mobile phase is collected.

[0135] (4) Lyophilization was performed to obtain 15.6 mg of LPS-free purslane galactoglucan POL-2.

[0136] 2.2 RAW264.7 cell recovery

[0137] Take out the frozen RAW264.7 macrophages from the liquid nitrogen tank and place them in 37°C warm water prepared in advance to allow the cells to thaw and return to room temperature within 1 to 2 minutes. Then, transfer the cells to a 15 mL centrifuge tube, add 3 mL of DMEM medium, centrifuge at 1000 r / min for 3 minutes, discard the supernatant, add 2 mL of DMEM complete medium to blow the cells, and then transfer to a 10 cm 2Place the cells in a culture dish and add 10 mL of culture medium to the dish. Shake the dish evenly. Observe the cell status and density under a microscope and place the cells in a cell culture incubator.

[0138] 2.3 RAW264.7 cell culture

[0139] After RAW264.7 macrophages were revived, they were grown in a DMEM high glucose medium containing 10% fetal bovine serum, 100 U / mL penicillin and 100 μg / mL streptomycin in a constant temperature incubator at 37°C and 5% CO2. LPS was used as a positive control.

[0140] 2.4 Cell viability assay

[0141] The MTT method was used to detect the viability of POL-2 cells. 4 The cells were inoculated at a density of 100 μL / well in a 96-well plate, incubated in an incubator at 37°C and 5% CO2 for 24 hours with complete culture medium containing 10% fetal bovine serum, and the upper culture medium was discarded. 100 μL of complete cell culture medium containing different concentrations of POL-2 (400, 200, 100, 50, 25, 12.5 μg / mL) was added. The blank control group was an equal amount of complete cell culture medium without polysaccharide. Six replicates were set for each group. After 24 hours of culture, 10 μL of MTT solution (5 mg / mL) was added to each well, and the incubation continued for 4 hours. The culture medium was carefully discarded, and 100 μL of DMSO was added to each well. The cells were incubated for 10 minutes and the OD value was detected at 490 nm.

[0142] 2.5 Effect of galactoglucan from purslane on NO release from macrophages detected by Griess method

[0143] 500 μL of cell suspension was inoculated into 24-well plates (5×10 5 / well), placed in a cell culture incubator for 24h. Discard the supernatant, replace the blank control group with complete culture medium, replace the positive LPS group with complete culture medium containing 1μg / mL LPS, and add complete culture medium containing different concentrations of POL-2 (200, 100, 50μg / mL) to the drug-treated group, and continue to culture for 24h. Take 50μL of culture solution and add it to a 96-well plate, add equal volumes of Griess Reagent I and Griess ReagentII to each well, shake and mix, measure the OD value at a wavelength of 540nm, and calculate the NO concentration.

[0144] 2.6 ELISA method to detect the effect of purslane galactoglucan on the secretion level of macrophage cytokines

[0145] The cells were 2×10 5The cells were inoculated into 24-well plates and cultured for 24 hours. Complete culture medium containing different concentrations of POL-2 (200, 100, 50 μg / mL) was added to the drug treatment groups, and 1 μg / mL LPS was used as a positive control. After 24 hours of continuous culture, the culture supernatant was collected and stored at -80°C for later use. The contents of TNF-α and IL-6 in the culture medium were detected according to the instructions of the ELISA kit.

[0146] 2.7 Western Blot analysis of the effect of galactoglucan from Portulaca oleracea on the expression of related proteins in the NF-κB pathway

[0147] The cell suspension density was adjusted to 5 × 10 5 / mL, 2mL was transferred to each well of a 6-well plate and placed in a cell culture incubator for 24h. Complete culture medium containing different concentrations of POL-2 (200, 100, 50μg / mL) was added to the drug-treated groups, and 1μg / mL LPS was used as a positive control. After 24h of treatment, an appropriate amount of lysis buffer was added to extract total protein. The extracted total protein was separated by SDS-PAGE electrophoresis and transferred to a PVDF membrane. Subsequently, it was blocked with 5% skim milk powder and incubated with primary antibody at 4°C overnight. The membrane was washed with TBST buffer and incubated with secondary antibody. The protein bands were developed in the Fluorchem Q imaging system. The grayscale of the bands was quantitatively analyzed using Image J software.

[0148] 3. Experimental results

[0149] 3.1 Effects on NO, IL-6 and TNF-α secretion in RAW264.7 cells

[0150] like Figure 5 As shown in the figure, after treating RAW264.7 cells with purslane galactoglucan for 24h, compared with the blank group, the expression of NO (attached Figure 5 B) and IL-6 ( Figure 5 D) showed a significant increase in the secretion of TNF-α in a dose-dependent manner (p<0.001). When the concentration of POL-2 was 50 μg, the secretion of TNF-α was significantly increased (p<0.01) ( Figure 5 Middle C) shows that Purslane galactoglucan POL-2 can promote the secretion of cytokines by RAW264.7 cells, effectively activate the immune response of macrophages, and has significant immunoenhancing activity.

[0151] 3.2 Effects on the expression of related proteins in the NF-κB pathway of RAW264.7 cells

[0152] like Figure 6As shown in the figure, compared with the blank group, the expression levels of p-P65 and p-IκB-α in cells were significantly increased after treatment with purslane galactoglucan, indicating that POL-2 can activate the NF-κB signaling pathway, awaken macrophages to participate in the immune response, and thus play an immunoregulatory role.

[0153] Example 4

[0154] Preparation of purslane galactoglucan tablets.

[0155] 1. Materials

[0156] The purslane galactoglucan and food or pharmaceutical grade starch are obtained by the same method as in Example 1.

[0157] 2. Prescription

[0158] Name of raw materials Dosage Purslane Galacto-glucan 200g lactose 190g Microcrystalline Cellulose 101 85g Sodium starch glycolate 10g 5% Povidone K30 in 50% ethanol 200mL Silicon dioxide 5g Magnesium Stearate 5g Made in total 5000 pieces

[0159] 3. Preparation process

[0160] The raw materials and auxiliary materials are crushed and sieved for use; the prescribed amount of PVPK30 is weighed according to the prescription, added to 50% ethanol solution, and vigorously stirred to fully disperse and dissolve it into a transparent and clear solution, which is sealed for use. Purslane galactoglucan, microcrystalline cellulose 101, lactose and sodium carboxymethyl starch are weighed according to the prescription, dry mixed for 15 minutes, added with the prepared adhesive, stirred for 3 minutes, and granulated with an 18-mesh screen. After drying the granules at 50-60°C, silicon dioxide and magnesium stearate are added and mixed for 2 minutes, and then granulated with a 16-mesh screen. Determine the content of the semi-finished product, press the tablets, and apply film coating to obtain the product.

[0161] Example 5

[0162] Preparation of galactoglucan capsules from Portulaca oleracea.

[0163] 1. Materials

[0164] The purslane galactoglucan and food or pharmaceutical grade starch are obtained by the same method as in Example 1.

[0165] 2. Prescription

[0166] Name of raw materials Dosage Purslane Galacto-glucan 500g starch 300g Made in total 5000 tablets

[0167] 3. Preparation process

[0168] Weigh the prescribed amount of purslane galactoglucan and starch, stir to mix thoroughly, add appropriate amount of talcum powder, wet granulate with ethanol, sieve and dry, and then fill into No. 2 capsule shells, with each capsule body filled with 80 mg of purslane galactoglucan, to prepare purslane galactoglucan capsules.

[0169] Example 6

[0170] Preparation of galactoglucan oral solution from purslane.

[0171] 1. Materials

[0172] The purslane galactoglucan obtained by the method of Example 1, and the food or pharmaceutical grade flavoring agent are and caramel flavor.

[0173] 2. Prescription

[0174] Name of raw materials Dosage Purslane Galacto-glucan 100g sucrose 0.6g Caramel flavor 0.1g Purified water 2000mL Made in total 500 pieces

[0175] 3. Preparation process

[0176] Weigh the prescribed amount of purslane galactoglucan, sucrose and caramel essence, add purified water to completely dissolve, filter through a 0.2 μm microporous filter membrane, and fill the filtrate into 4 mL per bottle using an oral liquid filling machine. Sterilize after sealing to obtain the product.

[0177] Example 7

[0178] Preparation of galactoglucan gel from purslane.

[0179] 1. Materials

[0180] The purslane galactoglucan obtained by the method of Example 1 uses cosmetic grade or food grade raw materials.

[0181] 2. Prescription

[0182] Name of raw materials Dosage Purslane Galacto-glucan 50g Carbomer 940 30g glycerin 250g Ethylparaben 2.5g Triethanolamine 25g Polysorbate 80 10g Propylene glycol 250mL Purified water 5L

[0183] 3. Preparation process

[0184] Weigh the prescribed amount of purslane galactoglucan, add 2.5L of water to dissolve and set aside; sprinkle the prescribed amount of carbomer 940 powder evenly on the surface of glycerin to fully moisten the carbomer, add 2L of water to fully swell the carbomer, then add the pre-dissolved polysaccharide solution, stir and mix evenly to obtain mixed solution I; dissolve ethylparaben in propylene glycol, and slowly add the mixture to obtain mixed solution II; then dissolve the prescribed amount of polysorbate 80 and triethanolamine in 0.5L of water, add the mixture to mixed solution II under stirring, stir evenly, and can the purslane galactoglucan gel.

[0185] Example 8

[0186] Preparation of Purslane Galacto-glucan Facial Cleanser.

[0187] 1. Materials

[0188] The purslane galactoglucan obtained by the method of Example 1 is made of cosmetic grade or food grade raw materials.

[0189] 2. Formulation

[0190] 0.5g of purslane galactoglucan, 3.0g of glycerin, 3.0g of butylene glycol, 0.6g of propylene glycol, 0.1g of sodium EDTA, 0.3g of guar gum, 2.0g of zinc dioxide, 4.0g of C12-15 alcohol benzoate, 3.0g of C12-20 alkyl glucoside, 0.5g of C14-22 alcohol, 1.2g of cetearyl alcohol, 0.2g of paraben, 0.3g of sodium stearate, 0.5g of dimethicone alcohol, 0.2g of polysorbate, and 60g of deionized water.

[0191] 3. Preparation process

[0192] Weigh the formula amount of galactoglucan from purslane and add purified water to completely dissolve it; take glycerin, butylene glycol, propylene glycol, sodium EDTA, guar gum, zinc dioxide, sodium stearate, C12-15 benzoate, C12-20 alkyl glucoside, C14-22 alcohol, cetearyl alcohol, add purified water and mix well; take paraben, dimethicone, polysorbate, add purified water and mix well. Mix the above prepared solutions, stir well and can them to obtain the product.

[0193] The technical features of the above-described embodiments may be arbitrarily combined. To make the description concise, not all possible combinations of the technical features in the above-described embodiments are described. However, as long as there is no contradiction in the combination of these technical features, they should be considered to be within the scope of this specification.

[0194] The above-mentioned embodiments only express several implementation methods of the present invention, and the description thereof is relatively specific and detailed, but it cannot be understood as limiting the scope of the invention patent. It should be pointed out that, for a person of ordinary skill in the art, several variations and improvements can be made without departing from the concept of the present invention, and these all belong to the protection scope of the present invention. Therefore, the protection scope of the present invention should not be limited to the scope described in this application.

Claims

1. A galactoglucan from purslane, It is characterized in that The purslane galactoglucan has a structure represented by the following general formula: In the chemical formula: n represents the number of sugar repeating units, n is a natural number; The weight average molecular weight of the purslane galactoglucan is 21000Da, the polydispersity coefficient is 1.9, and the molar ratio of galactose to glucose in the monosaccharide composition is 3.3:1; The monosaccharide connection mode of the purslane galactoglucan is: the β(1→4) galactose glycosidic bond is the main chain, and the side chain is replaced by α(1→4) glucose and α(1→6) glucose; The galactoglucan from purslane is obtained by extraction and purification from the dry aerial part of Portulaca oleracea L. of the family Portulacaceae.

2. The method for preparing the galactoglucan from Portulaca oleracea according to claim 1, It is characterized in that The method comprises the following steps: Extraction of Purslane Crude Polysaccharide: Weigh the crushed dry aerial part of Purslane, add 95% ethanol to extract twice at 65°C, each time for 3 hours, filter the residue, heat and extract it twice with deionized water at 80°C, each time for 2 hours, centrifuge the extract at 4000rpm×20min to obtain the supernatant; add 95% ethanol to the supernatant until the alcohol concentration is 40%, centrifuge at 4000rpm×20min to obtain a 40% alcohol precipitate and a 40% alcohol precipitate supernatant; add 95% ethanol to the above 40% alcohol precipitate supernatant under stirring until the alcohol concentration is 60%, centrifuge at 4000rpm×20min to obtain a 60% alcohol precipitate and an alcohol precipitate supernatant; wash the 40% and 60% alcohol precipitates with 95% ethanol and anhydrous ethanol respectively, re-dissolve the precipitate in water after centrifugation and freeze-dry to obtain crude polysaccharides POL40 and POL60; Purification of galactoglucan from purslane: Take crude polysaccharide POL60, dissolve it in 100mL deionized water, add an equal volume of 10% benzethonium chloride, stir while adding, let stand and centrifuge at 4000rpm, 20℃, 15min, add 95% ethanol to the obtained supernatant to make the final alcohol content 80%, stir while adding, let stand and precipitate with alcohol, centrifuge at 4000rpm, 20℃, 15min, the precipitate obtained is Purslane crude polysaccharide POL60q, take freeze-dried crude polysaccharide POL60q, re-dissolve it in deionized water, add 95% ethanol to make the final concentration of ethanol 40%, centrifuge at 4000rpm, 20℃, 15min, the precipitate obtained is POL60q40; POL60q40 is freeze-dried and taken 100mg, dissolved in 4mL deionized water and centrifuged at 4000rpm, 20℃, 15min, the upper liquid is filtered through a 0.45μm filter membrane and slowly and evenly injected into DEAE-Sepharose Fast The top of the flow column was eluted with deionized water, the flow rate was controlled at 0.1 mL / min, 2 mL was collected in each tube, and the polysaccharide content was detected by the phenol-sulfuric acid method. The elution curve of the polysaccharide component was drawn with the absorbance value as the ordinate and the number of tubes as the abscissa. The eluates belonging to the same elution peak were combined, and the sample with the largest area of ​​the elution curve was collected. The sample was concentrated under reduced pressure, freeze-dried in a vacuum, and refined purslane galactoglucan was obtained after multiple enrichments.

3. A pharmaceutical composition, It is characterized in that The pharmaceutical composition comprises an effective amount of the galactoglucan from Portulaca oleracea according to claim 1 and a pharmaceutically acceptable carrier.

4. A cosmetic product, It is characterized in that The cosmetic comprises an effective amount of purslane galactoglucan according to claim 1 and common cosmetic auxiliary materials.

5. A food product, It is characterized in that The food contains the purslane galactoglucan according to claim 1.

6. Use of the purslane galactoglucan according to claim 1 in the preparation of drugs for regulating immune activity.

7. Use of the purslane galactoglucan according to claim 1 in the preparation of a product for improving immunity.

8. Use of the purslane galactoglucan according to claim 1 in the preparation of cosmetics.

9. Use of the purslane galactoglucan according to claim 1 in preparing food.